全球预测诊断市场 - 2024-2031

预测诊断市场规模

全球预测诊断市场2023年达到486.7亿美元，预计2031年将达到1,391.8亿美元，2024-2031年预测期间复合年增长率为14.70%。

预测诊断采用客製化资料和一套诊断设备来提供精确、即时的见解并识别潜在问题。透过整合分子创新、基因组学应用和快速研发流程，预测诊断可以帮助为营运带来有影响力和可衡量的进步。

使用预测诊断，所应用的演算法可以分析和识别所提供的资料中的模式，并计算未来即将发生故障的机率。预测诊断的主要应用是疾病管理。

预测诊断市场动态

不断增加的产品发布和公司之间的合作

主要公司之间不断增加的产品发布和合作预计将推动市场成长。公司正在采取合作、伙伴关係和收购等策略来扩大市场成长。

For instance, in September 2022, QIAGEN and Neuron23 Inc., a biotechnology organization focused on designing precision medicines for genetically defined neurological and immunological diseases, agreed to create a companion diagnostic for Neuron23's brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson's疾病.

此外，Tempus 还推出了新的 DPYD 演算法，作为其不断增长的实验室开发的预测演算法测试集合的最新成员。因此，预计上述因素将在预测期内推动市场成长。

缺乏预测诊断的专业知识

复杂的预测诊断结果可能难以解释，特别是对于非该领域专业人士的从业人员。如果临床医生不完全理解这些结果，他们可能会发现很难将这些结果纳入患者照护方案中。如果医疗保健专业人员缺乏足够的培训或预测诊断经验，他们可能不愿意为患者订购这些测试。这可能会导致这些测试的使用率较低并阻碍市场的扩展。

预测诊断市场区隔分析

全球预测诊断市场根据类型、应用、最终用户和地区进行细分。

肿瘤学领域预计将主导市场成长

肿瘤学领域占据最大的市场份额。癌症是全世界最主要的死亡原因。最常见的癌症是乳癌、结肠癌、肺癌、直肠癌和摄护腺癌，2020 年死亡人数接近 1,000 万人，占六分之一。

这些公司正在推出各种用于肿瘤学的产品和平台，随着癌症病例的不断增加，对这些产品的需求增加，这可以扩大其应用范围。

例如，2023 年 4 月，Certis Oncology Solutions 推出了 CertisAI，这是一个新的预测医学平台，利用巨量资料、统计演算法和机器学习 (ML) 根据基因表现生物标记预测药物疗效。

此外，2021 年，Tempus 推出了新的 DPYD 演算法，作为其不断增长的实验室开发的预测演算法测试集合的最新补充。此测试评估 DPYD（二氢嘧啶脱氢酶）基因的相关突变，帮助医生更好地识别某些化疗药物潜在毒性风险的患者，以避免不良反应。因此，对癌症诊断的日益关注预计将推动预测期内该细分市场的成长。

预测诊断市场地理分析

预计北美将在预测诊断市场份额中占据重要地位

北美在预测诊断市场上占据主导地位，预计在预测期内也将呈现相同的趋势。改善的医疗基础设施、不断上升的传染病发病率、活跃的区域主要参与者以及该地区方便的产品供应是推动该地区市场的主要因素。

例如，2021 年 6 月，Predictive Health Diagnostics Company, Inc. 与分销合作伙伴 Patia Europe SL 合作推出了第二个诊断测试 DIABETESpredict。

此外，例如，2021年12月，罗氏收购了TIB Molbiol Group。 TIB Molbiol 将继续作为诊断部门的子公司开展工作。罗氏和 TIB Molbiol 将打造快速开发新病原体和潜在健康威胁（例如传染病）检测方法的能力。因此，上述因素正在推动市场成长，并有望使该地区保持主导地位。

COVID-19 对预测诊断市场的影响分析

由于全球对 COVID-19 诊断的关注，诊断的必要性已得到更广泛的认识。这使得人们充分认识到预测诊断在其他领域的可能性。 COVID-19 诊断的快速发展引发了分子诊断和人工智慧 (AI) 等领域的创新。这些进展可用于建立新的、增强的预测诊断仪器。 COVID-19 检测能够识别感染患者，这引起了人们对应用类似策略来早期诊断其他疾病（包括慢性病）的兴趣。

预测诊断市场竞争格局

市场的主要全球参与者包括 Abbott Laboratories、Certis Oncology Solutions, Inc.、Proteomics International Laboratories Ltd、QIAGEN NV、Prometheus Laboratories Inc.、F. Hoffmann-La Roche Ltd.、Illumina Inc.、Myriad Genetics、Exact Sciences Corporation和信实生命科学公司。除其他外。

为什么购买报告？

根据类型、应用程式、最终用户和地区可视化全球预测诊断市场细分，并了解关键商业资产和参与者。

透过分析趋势和共同开发来识别商业机会。

Excel资料表，包含所有细分市场预测诊断市场层级的大量资料点。

PDF 报告由详尽的质性访谈和深入研究后的综合分析组成。

产品映射以 Excel 形式提供，包含所有主要参与者的关键产品。

全球预测诊断市场报告将提供约 53 张表格、47 张图和 176 页。

2024 年目标受众

製造商/买家

产业投资者/投资银行家

研究专业人员

新兴公司

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

• 影响因素
  • 司机
    • 不断增加的产品发布和公司之间的合作
  • 限制
    • 缺乏预测诊断的专业知识
  • 机会
  • 影响分析

第 5 章：产业分析

• 波特五力分析
• 供应链分析
• 定价分析
• 监管分析
• 报销分析
• 专利分析
• SWOT分析
• DMI 意见

第 6 章：COVID-19 分析

第 7 章：按类型

• 症状前
• 倾向性

第 8 章：按申请

• 心血管疾病
• 神经系统疾病
• 遗传疾病
• 肿瘤学
• 其他的

第 9 章：最终用户

• 诊断中心
• 基因实验室和诊所
• 研究和学术机构

第 10 章：按地区

• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地区
• 亚太
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 亚太其他地区
• 中东和非洲

第 11 章：竞争格局

• 竞争场景
• 市场定位/份额分析
• 併购分析

第 12 章：公司简介

• Abbott Laboratories
• 公司概况
• 产品组合和描述
• 财务概览
• 主要进展
• Certis Oncology Solutions, Inc.
• Proteomics International Laboratories Ltd
• QIAGEN NV
• Prometheus Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Illumina Inc.
• Myriad Genetics
• Exact Sciences Corporation
• Reliance Life Sciences. (LIST NOT EXHAUSTIVE)

第 13 章：附录

Predictive Diagnostics Market Size

The Global Predictive Diagnostics Market reached US$ 48.67 billion in 2023 and is expected to reach US$ 139.18 billion by 2031, growing at a CAGR of 14.70% during the forecast period 2024-2031.

Predictive diagnostics employs customized data and a suite of diagnostic devices to deliver precise, real-time insights and identify potential problems. By integrating molecular innovations, genomics applications, and rapid R&D processes, predictive diagnostics can assist in delivering impactful and measurable advancements to operations.

Using predictive diagnostics, the applied algorithms can analyze and recognize patterns within delivered data and calculate probabilities of upcoming failures in the future. The main application of predictive diagnostics is disease management.

Predictive Diagnostics Market Dynamics

The increasing product launches and collaborations among companies

Increasing product launches and collaborations among the major companies are expected to drive market growth. Companies are adopting strategies such as collaborations, partnerships, and acquisitions to expand the market growth.

For instance, in September 2022, QIAGEN and Neuron23 Inc., a biotechnology organization focused on designing precision medicines for genetically defined neurological and immunological diseases, agreed to create a companion diagnostic for Neuron23's brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson's disease.

Additionally, Tempus unveiled its new DPYD algorithm as its most recent addition to its growing collection of predictive algorithm laboratory-developed tests. Thus, the above factors are expected to drive the market growth during the forecast period.

Lack of expertise in predictive diagnostics

Complex predictive diagnostic results might be difficult to interpret, particularly for practitioners who are not professionals in this field. Clinicians can find it difficult to incorporate these outcomes into patient care regimens if they do not fully comprehend them. Healthcare professionals could be reluctant to order these tests for their patients if they lack enough training or experience with predictive diagnostics. This may result in a low use of these tests and impede the expansion of the market.

Predictive Diagnostics Market Segment Analysis

The global predictive diagnostics market is segmented based on type, application, end-user and region.

Oncology segment is expected to dominate the market growth

The oncology segment accounts for the largest market share. Cancer is the foremost cause of death worldwide. The most common cancers are breast, colon, lung, rectum, and prostate Cancer accounted for almost 10 million deaths in 2020 or nearly one in six.

The companies are introducing a variety of products and platforms to make use in oncology, as there is a growing number of cancer cases, the demand for these products rises which can expand their application.

For instance, in April 2023, Certis Oncology Solutions launched CertisAI, a new predictive medicine platform that utilizes big data, statistical algorithms, and machine learning (ML) to predict drug efficacy based on gene expression biomarkers.

Additionally, in 2021, Tempus introduced its new DPYD algorithm as its most recent addition to its growing collection of predictive algorithm laboratory-developed tests. The test assesses for relevant mutations in the DPYD (dihydropyrimidine dehydrogenase) gene and helps physicians better identify patients at potential risk for toxicity to certain chemotherapies, aiming to avoid adverse effects. Thus, increasing focus on cancer diagnostics is expected to drive the segment growth during the forecast period.

Predictive Diagnostics Market Geographical Analysis

North America is expected to hold a significant position in the predictive diagnostics market share

North America dominates the market for predictive diagnostics and is anticipated to show an equivalent trend over the forecast period. Improved healthcare infrastructure, rising infectious illness rates, active regional key players, and convenient product availability in the area are the main factors driving the market in the region.

For instance, in June 2021, Predictive Health Diagnostics Company, Inc. launched its second diagnostic test, DIABETESpredict, in collaboration with distribution partner Patia Europe SL.

Additionally, For instance, in December 2021, Roche acquired the TIB Molbiol Group. TIB Molbiol will continue to work as a subsidiary within the Diagnostics division. Roche and TIB Molbiol will create their capabilities for the fast development of assays for emerging pathogens and potential health threats, such as infectious diseases. Thus, the above factors are driving the market growth and are expected to hold the region in the dominant position.

COVID-19 Impact Analysis On Predictive Diagnostics Market

The necessity of diagnostics in general has become more widely recognised due to the global focus on COVID-19 diagnosis. This caused people to fully recognize the possibilities of predictive diagnoses in other fields. Innovations in fields like molecular diagnostics and artificial intelligence (AI) were sparked by the quick development of COVID-19 diagnostics. These developments can be used to create fresh, enhanced predictive diagnostic instruments. The ability of COVID-19 testing to identify infected patients has raised interest in applying comparable strategies for the early diagnosis of other diseases, including chronic ailments.

Predictive Diagnostics Market Competitive Landscape

The major global players in the market include Abbott Laboratories, Certis Oncology Solutions, Inc., Proteomics International Laboratories Ltd, QIAGEN N.V., Prometheus Laboratories Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., Myriad Genetics, Exact Sciences Corporation, and Reliance Life Sciences. among others.

Why Purchase the Report?

To visualize the global predictive diagnostics market segmentation based on type, application, end user and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of predictive diagnostics market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global predictive diagnostics market report would provide approximately 53 tables, 47 figures and 176 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Application
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The increasing product launches and collaborations among companies
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of expertise in predictive diagnostics
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Presymptomatic *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Predispositional

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Cardiovascular Diseases*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Neurological Diseases
• 8.4. Genetic Diseases
• 8.5. Oncology
• 8.6. Others

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Diagnostic Centers*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Genetic Laboratories and Clinics
• 9.4. Research and Academic Institutes

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
    • 10.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.3.1. U.S.
    • 10.2.3.2. Canada
    • 10.2.3.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
    • 10.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.4.1. Germany
    • 10.3.4.2. UK
    • 10.3.4.3. France
    • 10.3.4.4. Italy
    • 10.3.4.5. Spain
    • 10.3.4.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
    • 10.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.4.1. Brazil
    • 10.4.4.2. Argentina
    • 10.4.4.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
    • 10.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.4.1. China
    • 10.5.4.2. India
    • 10.5.4.3. Japan
    • 10.5.4.4. Australia
    • 10.5.4.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
    • 10.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Abbott Laboratories*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Certis Oncology Solutions, Inc.
• 12.3. Proteomics International Laboratories Ltd
• 12.4. QIAGEN N.V.
• 12.5. Prometheus Laboratories Inc.
• 12.6. F. Hoffmann-La Roche Ltd.
• 12.7. Illumina Inc.
• 12.8. Myriad Genetics
• 12.9. Exact Sciences Corporation
• 12.10. Reliance Life Sciences. (LIST NOT EXHAUSTIVE)

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us